Details

Project TitleMajor Peptide Epitopes for the Pathogenic T Helper Cells of Human SLE
Track Code1999-016
Short Description

Very low dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T-cell subsets in a mouse model with potential human applications.

#therapeutics #diseasemodel #autoimmunity #peptide

Abstract

Investigators at Northwestern University have identified peptides localized to distinct regions of histone proteins that are recognized by autoimmune T-cells in Systemic Lupus Erythematosus (SLE). These peptides, when administered in a mouse model of SLE, delay onset as well as significantly decrease the severity of the disease. The use of these peptides in the treatment of SLE would offer a more specific intervention by targeting the immune cells that mediate the pathogenic effects, but without the generalized immunosuppressive and toxic effects of the drugs currently being used. Importantly, these peptides appear to be effective even when the autoimmune disease is already established. The peptides can also be used as a sensitive diagnostic and/or prognostic tool for tracking autoimmune T-cells that may appear long before symptoms of the disease itself are manifested.

Also available: NU 2000-032

 
TagsTHERAPEUTICS: disease model, THERAPEUTICS: peptide, autoimmunity
 
Posted DateMar 7, 2013 2:39 PM

Inventor(s)

Syamal Datta*

Arunan Kaliyaperumal

Applications

• Therapeutics: SLE
• Diagnostic and Prognostic Tool

Advantages

• Diminished severity of disease
• Less toxic side effects

Publications

IP Status

Issued US Patent No.6,468,537

Contact Information

Becky Crump, PhD
Associate Director
(p) 847-491-3630
(e) beckyc@northwestern.edu